Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12465280 | 0.98 | MEN1 (0.44) | MEN1KMT2ACYP2D6CYP2C19L3MBTL3 | |
| SCHEMBL23653473 | 0.93 | MEN1 (0.44) | MEN1KMT2ACYP2D6CYP2C19L3MBTL3 | |
| SCHEMBL22175015 | 0.88 | KMT2A (0.50) | MEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL24619026 | 0.88 | KMT2A (0.50) | MEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL24221674 | 0.86 | HTR6 (0.42) | MEN1KMT2AL3MBTL3L3MBTL1OPRM1 | |
| SCHEMBL22969970 | 0.84 | MEN1 (0.36) | MEN1KMT2ACYP2D6CYP2C19L3MBTL3 | |
| SCHEMBL12605203 | 0.83 | MEN1 (0.42) | MEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL7215234 | 0.83 | OPRL1 (0.50) | MEN1KMT2ACYP2D6CYP2C19OPRM1 | |
| SCHEMBL24146229 | 0.82 | OPRL1 (0.45) | MEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL20386431 | 0.82 | OPRL1 (0.45) | MEN1KMT2AOPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943086-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | BioSplice Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3494115-B1 | N-(PHENYLSULFONYL)BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2020140052-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020140053-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| EP-3569601-A2 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | The Regents of The University of Michigan (US) | 2019-11-20 | — | — | EP | disclosed |
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | SGX PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | MAP3K20, TTK, MAP3K19 | MEN1 3157/4885KMT2A 851/4885CYP2D6 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.